Neutralizing antibody titers against field strains of bovine viral diarrhea virus after vaccination with three commercial vaccines

Modified killed vaccines against bovine viral diarrhea virus (BVDV) are used worldwide. In the present study, the crossneutralizationantibody responses against field strains from seven subgenotypes of BVDV-1 and one subgenotype of BVDV-2 wereevaluated using sera obtained by three inactivated commercial vaccines. One vaccine contained both BVDV-1 and BVDV-2 strains,while the others contained only BVDV-1a. Three vaccine groups, each containing five calves, were vaccinated two times with 30-day intervals. The antibody titers were evaluated by virus neutralization assay. The monovalent vaccine induced the highest antibodytiters. Significant levels of neutralizing antibody titers were maintained up to the last sampling time. Although one vaccine containedthe BVDV-2 strain, the lowest antibody titers were detected against field strains from BVDV-2, BVDV-1b, and BVDV-1r. This studyindicated that cross-protective immune responses with the most common international BVDV vaccine strains need to be evaluated withchallenge experiments against field strains for efficient protection.

PDF

___

1. Ståhl K, Alenius S. BVDV control and eradication in Europe – an update. Jpn J Vet Res 2012; 60: 31-39.
2. Reddy JR, Xue W, Rivera S, Minocha HC. Antigenic differences between a field isolate and vaccine strains of bovine viral diarrhea virus. J Clin Microbiol 1995; 33: 2159-2161.
3. Yeşilbağ K, Alpay G, Becher P. Variability and global distribution of subgenotypes of bovine viral diarrhea virus. Viruses 2017; 9: 128.
4. Xue F, Zhu YM, Li J, Zhu LC, Ren XG et al. Genotyping of bovine viral diarrhea viruses from cattle in china between 2005 and 2008. Vet Microbiol 2010; 143: 379-383.
5. Yeşilbağ K, Förster C, Bank-Wolf B, Yılmaz Z, Alkan F et al. Genetic heterogeneity of bovine viral diarrhoea virus (BVDV) isolates from Turkey: Identification of a new subgroup in BVDV-1. Vet Microbiol 2008; 130: 258-267.
6. Yeşilbağ K, Förster C, Ozyiğit MO, Alpay G, Tuncer P et al. Characterisation of bovine viral diarrhoea virus (BVDV) isolates from an outbreak with haemorrhagic enteritis and severe pneumonia. Vet Microbiol 2014; 169: 42-49.
7. Giangaspero M, Harasawa R, Weber L, Belloli A. Taxonomic and epidemiological aspect of the bovine viral diarrhoea virus 2 through the observation of the secondary structures in the 5’ genomic untranslated region. Vet Ital 2008; 44: 319-345.
8. Ridpath JF. Practical significance of heterogeneity among BVDV strains: impact of biotype and genotype on U.S. control programs. Prev Vet Med 2005; 72: 17-30.
9. Fulton RW, Ridpath JF, Confer AW, Saliki JT, Burge LJ et al. Bovine viral diarrhea virus antigenic diversity: impact on disease and vaccination programmes. Biologicals 2003; 31: 89-95.
10. Zimmer GM, Wentink GH, Bruschke C, Westenbrink FJ, Brinkhof J et al. Failure of foetal protection after vaccination against an experimental infection with bovine virus diarrhea virus. Vet Microbiol 2002; 89: 255-265.
11. Fulton RW. Impact of species and subgenotypes of bovine viral diarrhea virus on control by vaccination. Anim Health Res Rev 2015; 16: 40-54.
12. Wernike K, Michelitsch A, Aebischer A, Schaarschmidt U, Konrath A et al. The occurrence of a commercial Npro and Erns double mutant BVDV-1 live-vaccine strain in newborn calves. Viruses 2018; 10: 274.
13. Cedillio RS. Charakterisierung ruminanter Pestiviren mittels Polymerasekettenreaktion und monoklonaler Antikörper. Justus Liebig University Giessen, GER (Dissertation), 2004.
14. Beer M, Hehnen HR, Wolfmeyer A, Poll G, Kaaden OR et al. A new inactivated BVDV genotype I and II vaccine. An immunisation and challenge study with BVDV genotype I. Vet Microbiol 2000; 77: 195-208.
15. Deutskens F, Lamp B, Riedel CM, Wentz E, Lochnit G et al. Vaccine-induced antibodies linked to bovine neonatal pancytopenia (BNP) recognize cattle major histocompatibility complex class I (MHC I). Vet Res 2011; 42: 97.
16. Fernández F, Costantini V, Barrandeguy M, Parreño V. Evaluation of experimental vaccines for bovine viral diarrhea in bovines, ovines and guinea pigs. Rev Argent de Microbiol 2009; 41: 86-91.
17. Kalaycioglu AT. Bovine viral diarrhoea virus (BVDV) diversity and vaccination. Vet Quart 2007; 29: 60-67.
18. Reber AJ, Tanner M, Okinaga T, Woolums AR, Williams S et al. Evaluation of multiple immune parameters after vaccination with modified live or killed bovine viral diarrhea virus vaccines. Comp Immunol Microbiol 2006; 29: 61-77.
19. Ridpath JF, Dominowski P, Mannan R, Yancey JR, Jackson JA et al. Evaluation of three experimental bovine viral diarrhea virus killed vaccines adjuvanted with combinations of Quil A cholesterol and dimethyldioctadecylammonium (DDA) bromide. Vet Res Commun 2010; 34: 691-702.
20. Rodning SP, Marley MS, Zhang Y, Eason AB, Nunley CL et al. Comparison of three commercial vaccines for preventing persistent infection with bovine viral diarrhea virus. Theriogenology 2010; 73: 1154-1163.
21. Baccili CC, Martin CC, Decaris N, Madureira KM, Chase et al. Effects of 3 different commercial vaccines formulations against BVDV and BHV-1 on the inflammatory response of Holstein heifers. Vet Sci 2019; 6 (3): e69.
22. Downey-Slinker ED, Ridpath JF, Sawyer JE, Skow LC, Herring AD. Antibody titers to vaccination are not predictive of level of protection against a BVDV type 1b challenge in Bos indicus - Bos taurus steers. Vaccine 2016; 34 (42): 5053-5059.
23. Riitho V, Larska M, Strong R, La Rocca SA, Locker N et al. Comparative analysis of adaptive immune responses following experimental infections of cattle with bovine viral diarrhoea virus-1 and an Asiatic atypical ruminant pestivirus. Vaccine 2018; 36: 4494-4500.
24. Sarikaya S, Azkur AK, Gazyagci S. Inactivated bovine viral diarrhea virus vaccine trigger leukopenia and lymphopenia on calves. Acta Scientiae Veterinariae 2011; 39: 994.
25. Baccili CC, Sobreira NM, Silva BT, Pituco EM, Gomes V. Interface between maternal antibodies and natural challenge for bovine viral diarrhea virus (BVDV) in Holstein Heifers. Acta Scientiae Veterinariae 2016; 44: 1406.
26. Fulton RW, Briggs RE, Ridpath JF, Saliki JT, Confer AW et al. Transmission of bovine viral diarrhea virus 1b to susceptible and vaccinated calves by exposure to persistently infected calves. Can J Vet Res 2005; 69: 161-169.
27. Grooms D, Bolin SR, Coe PH, Borges RJ, Coutu CE. Fetal protection against continual exposure to bovine viral diarrhea virus following administration of a vaccine containing an inactivated bovine viral diarrhea virus fraction to cattle. Am J Vet Res 2007; 68: 1417-1422.
28. Bolin SR, Ridpath JF. Assessment of protection from systemic infection or disease afforded by low to intermediate titers of passively acquired neutralizing antibody against bovine viral diarrhea virus in calves. Am J Vet Res 1995; 56: 755-759.
29. Fulton RW, Burge LJ. Bovine viral diarrhea virus types 1 and 2 antibody response in calves receiving modified live virus or inactivated vaccines. Vaccine 2001; 19: 264-274.
30. Alpay G, Yeşilbağ K. Serological relationships among subgroups in bovine viral diarrhoea virus genotype 1 (BVDV- 1). Vet Microbiol 2015; 175: 1-6.
31. Bachofen C, Stalder H, Braun U, Hilbe M, Ehrensperger F et al. Co-existence of genetically and antigenically diverse bovine viral diarrhoea viruses in an endemic situation. Vet Microbiol 2008; 131: 93-102.
32. Fulton RW, Step DL, Ridpath JF, Saliki JT, Confer AW et al. Response of calves persistently infected with noncytopathic bovine viral diarrhea virus (BVDV) subtype 1b after vaccination with heterologous BVDV strains in modified live virus vaccines and Mannheimia haemolytica bacterin-toxoid. Vaccine 2003; 21: 2980-2985.
33. Kurcubic VS, Milic NS, Djokovic RD, Ilic ZZ. Evaluation of immunogenic properties of monovalent and polyvalent inactivated bovine virus diarrhea virus (BVDV). Afr J Microbiol Res 2011; 5: 2422-2427.
34. Fulton RW. Vaccines. In: Goyal SM, Ridpath JA, editors. Bovine Viral Diarrhea Virus: Diagnosis, Management and Control. 1st ed. Ames, IA, USA: Blackwell Publishing, 2005. pp. 209-222.